Ameritas Investment Partners Inc. Cuts Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Ameritas Investment Partners Inc. decreased its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 3.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,156 shares of the company’s stock after selling 81 shares during the period. Ameritas Investment Partners Inc.’s holdings in Krystal Biotech were worth $384,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Krystal Biotech by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock valued at $302,182,000 after acquiring an additional 35,632 shares during the last quarter. Jennison Associates LLC lifted its holdings in shares of Krystal Biotech by 112.5% in the 4th quarter. Jennison Associates LLC now owns 724,344 shares of the company’s stock valued at $89,862,000 after acquiring an additional 383,495 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Krystal Biotech by 5.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 550,806 shares of the company’s stock valued at $68,337,000 after acquiring an additional 30,169 shares during the last quarter. TimesSquare Capital Management LLC lifted its holdings in shares of Krystal Biotech by 103.6% in the 4th quarter. TimesSquare Capital Management LLC now owns 250,470 shares of the company’s stock valued at $31,073,000 after acquiring an additional 127,435 shares during the last quarter. Finally, First Turn Management LLC bought a new position in shares of Krystal Biotech in the 4th quarter valued at about $30,045,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Trading Down 0.1 %

Shares of Krystal Biotech stock traded down $0.27 on Wednesday, hitting $206.92. 146,193 shares of the company traded hands, compared to its average volume of 380,223. The stock’s 50 day moving average price is $178.73 and its 200-day moving average price is $159.46. Krystal Biotech, Inc. has a 52 week low of $93.95 and a 52 week high of $214.98. The company has a market cap of $5.91 billion, a PE ratio of 110.80 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, May 6th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.20 by ($0.17). The firm had revenue of $45.25 million for the quarter, compared to analysts’ expectations of $47.37 million. During the same period in the previous year, the company earned ($1.76) earnings per share. The business’s quarterly revenue was up 452400.0% on a year-over-year basis. As a group, research analysts anticipate that Krystal Biotech, Inc. will post 2.15 EPS for the current fiscal year.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the completion of the sale, the insider now owns 1,525,882 shares of the company’s stock, valued at $268,189,020.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the transaction, the insider now directly owns 1,525,882 shares of the company’s stock, valued at $268,189,020.32. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Julian S. Gangolli sold 20,000 shares of Krystal Biotech stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $164.13, for a total transaction of $3,282,600.00. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.

Analyst Ratings Changes

KRYS has been the subject of a number of analyst reports. Stifel Nicolaus reaffirmed a “buy” rating and issued a $204.00 price target (up previously from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. HC Wainwright reissued a “buy” rating and issued a $200.00 price objective on shares of Krystal Biotech in a research note on Monday, May 6th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, Krystal Biotech currently has an average rating of “Buy” and an average price target of $177.63.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).